Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures

• Published in: Frontiers in immunology Vol. 13; p. 955063
• Main Authors: Hossain, Sultana Mehbuba, Gimenez, Gregory, Stockwell, Peter A., Tsai, Peter, Print, Cristin G., Rys, Janusz, Cybulska-Stopa, Bozena, Ratajska, Magda, Harazin-Lechowska, Agnieszka, Almomani, Suzan, Jackson, Christopher, Chatterjee, Aniruddha, Eccles, Michael R.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 28.09.2022
• Subjects: de-differentiation; Immunology; immunotherapy; melanoma; neoantigen; neural crest-like; tumour mutation burden

Melanoma is a highly aggressive skin cancer, which, although highly immunogenic, frequently escapes the body’s immune defences. Immune checkpoint inhibitors (ICI), such as anti-PD1, anti-PDL1, and anti-CTLA4 antibodies lead to reactivation of immune pathways, promoting rejection of melanoma. However...